JPS5533479A - Novel benzimidazole - Google Patents

Novel benzimidazole

Info

Publication number
JPS5533479A
JPS5533479A JP10730779A JP10730779A JPS5533479A JP S5533479 A JPS5533479 A JP S5533479A JP 10730779 A JP10730779 A JP 10730779A JP 10730779 A JP10730779 A JP 10730779A JP S5533479 A JPS5533479 A JP S5533479A
Authority
JP
Japan
Prior art keywords
novel benzimidazole
benzimidazole
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP10730779A
Other languages
Japanese (ja)
Other versions
JPS6324996B2 (en
Inventor
Ausuteru Fuorukuharuto
Haidaa Yoahimu
Eberurain Uorufugangu
Deiederen Buirii
Haaruman Barutaa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Dr Karl Thomae GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Karl Thomae GmbH filed Critical Dr Karl Thomae GmbH
Publication of JPS5533479A publication Critical patent/JPS5533479A/en
Publication of JPS6324996B2 publication Critical patent/JPS6324996B2/ja
Granted legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F8/00—Arrangements for software engineering
    • G06F8/30—Creation or generation of source code
    • G06F8/31—Programming languages or programming paradigms
    • G06F8/313—Logic programming, e.g. PROLOG programming language
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Software Systems (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Theoretical Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Computing Systems (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP10730779A 1978-08-25 1979-08-24 Novel benzimidazole Granted JPS5533479A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19782837161 DE2837161A1 (en) 1978-08-25 1978-08-25 5-Alkyl:pyridazinyl substd. benzimidazole derivs. - useful as cardiovascular agents, antivirals, interferon inducers and ulcer inhibitors

Publications (2)

Publication Number Publication Date
JPS5533479A true JPS5533479A (en) 1980-03-08
JPS6324996B2 JPS6324996B2 (en) 1988-05-23

Family

ID=6047905

Family Applications (1)

Application Number Title Priority Date Filing Date
JP10730779A Granted JPS5533479A (en) 1978-08-25 1979-08-24 Novel benzimidazole

Country Status (3)

Country Link
JP (1) JPS5533479A (en)
DE (1) DE2837161A1 (en)
ZA (1) ZA794472B (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61194083A (en) * 1985-02-19 1986-08-28 メルク・パテント・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング Benzimidazolylpyridazinone compound
JPH01254627A (en) * 1988-02-24 1989-10-11 Dr Karl Thomae Gmbh Pharmaceutical composition
JPH04210919A (en) * 1990-01-20 1992-08-03 Dr Karl Thomae Gmbh Oral administrating preparation of pimobendan
JP2006219452A (en) * 2005-02-14 2006-08-24 Toa Eiyo Ltd Method for producing pimobendan and its intermediate
JP2009504758A (en) * 2005-08-15 2009-02-05 アイアールエム・リミテッド・ライアビリティ・カンパニー Compounds and compositions as TPO mimetics

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3804490A1 (en) * 1988-02-12 1989-08-24 Heumann Pharma Gmbh & Co SUBSTITUTED 6-PHENYLDIHYDRO-3 (2H) -PYRIDAZINONE, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
DE3814057A1 (en) * 1988-04-26 1989-11-09 Heumann Pharma Gmbh & Co 6-OXO-PYRIDAZINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
DE3913597A1 (en) * 1989-04-25 1990-11-08 Heumann Pharma Gmbh & Co DIAZINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
NZ568694A (en) 2005-11-09 2011-09-30 Zalicus Inc Method, compositions, and kits for the treatment of medical conditions
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
AU2009256157B2 (en) 2008-06-04 2014-12-18 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EA201391254A1 (en) 2011-03-01 2014-02-28 Синерджи Фармасьютикалз Инк. METHOD FOR OBTAINING GUANYLATZCLAZE AGONISTS C
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
CA2902348C (en) 2013-02-25 2021-11-30 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
WO2014197720A2 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same
US20160184387A1 (en) 2013-08-09 2016-06-30 Dominique Charmot Compounds and methods for inhibiting phosphate transport
CN114340631A (en) 2019-05-21 2022-04-12 阿德利克斯股份有限公司 Combination for reducing serum phosphate in a patient

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61194083A (en) * 1985-02-19 1986-08-28 メルク・パテント・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング Benzimidazolylpyridazinone compound
JPH01254627A (en) * 1988-02-24 1989-10-11 Dr Karl Thomae Gmbh Pharmaceutical composition
JPH04210919A (en) * 1990-01-20 1992-08-03 Dr Karl Thomae Gmbh Oral administrating preparation of pimobendan
JP2608183B2 (en) * 1990-01-20 1997-05-07 ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング Pimobendan oral dosage form
JP2006219452A (en) * 2005-02-14 2006-08-24 Toa Eiyo Ltd Method for producing pimobendan and its intermediate
JP4714921B2 (en) * 2005-02-14 2011-07-06 トーアエイヨー株式会社 Production method of pimobendan and its intermediate
JP2009504758A (en) * 2005-08-15 2009-02-05 アイアールエム・リミテッド・ライアビリティ・カンパニー Compounds and compositions as TPO mimetics

Also Published As

Publication number Publication date
ZA794472B (en) 1981-04-29
JPS6324996B2 (en) 1988-05-23
DE2837161A1 (en) 1980-03-06

Similar Documents

Publication Publication Date Title
EG13913A (en) Novel n-heterocyclyl-4-piperidinamines
CS520079A2 (en) Nosna soustava snimaci hlavice
JPS54122278A (en) 99aminoodibenzopyranes
JPS5533479A (en) Novel benzimidazole
ZA794379B (en) Novel spiro-oxazolidindiones
BG27580A1 (en) Two- poled pelvis- thight articulation- set
CS761579A2 (en) Elektricky vypinac se samocinnym zhasenim elektrickeho oblouku
CS333379A2 (en) Upinaci zarizeni
GB2025061B (en) Hot-wireanemometer
CS353979A2 (en) Zpusob extrakce organickych slozek z rostlinnych materialu
JPS54154730A (en) Novel dialkoxybenzamides
CS290179A2 (en) Plynova vybojka
JPS5549432A (en) Scooperrexcavator
JPS54150667A (en) Ptccresistor
PH17031A (en) Novel phenoxyalkyloxazolines
GB2038323B (en) N-acyl-o-phenylenediamines
JPS5555069A (en) Autobicycle
HK42683A (en) Phenoxyalkanamides
GB2024800B (en) Glass-cutter
JPS54146422A (en) Hhsteel
CS556679A2 (en) Zpusob vyroby derivatu chlorambucilu
BG31541A1 (en) Ornitopter
GB2027016B (en) Substituted thio-sulphinyl-and sulphonyl-alkyl benzimidazole carbamates
CA43944S (en) Compositiontable
CA44301S (en) Hairsetter

Legal Events

Date Code Title Description
EXPY Cancellation because of completion of term